Analytical Data
-
Gene name
CDKN3
- Application
-
Alternative Names
CDKN3；CDI1；CIP2；KAP；Cyclin-dependent kinase inhibitor 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16667
-
Expression Region
1-212aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MKPPSSIQTS EFDSSDEEPI EDEQTPIHIS WLSLSRVNCS QFLGLCALPG CKFKDVRRNV QKDTEELKSC GIQDIFVFCT RGELSKYRVP NLLDLYQQCG IITHHHPIAD GGTPDIASCC EIMEELTTCL KNYRKTLIHC YGGLGRSCLV AACLLLYLSD TISPEQAIDS LRDLRGSGAI QTIKQYNYLH EFRDKLAAHL SSRDSQSRSV SR
-
Molecular Weight
26 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDKN3, or Cyclin-dependent kinase inhibitor 3, is a pivotal protein involved in regulating the cell cycle by inhibiting cyclin-dependent kinases (CDKs). The dysregulation of CDKN3 has been associated with various cancers, making it a potential target for tumorigenesis research and therapeutic interventions. CDKN3 functions by controlling the transition from the G1 to S phase of the cell cycle, and its downregulation or mutation can lead to unchecked cellular proliferation, a hallmark of cancer. Studies have shown that alterations in CDKN3 expression levels can influence the sensitivity of cancer cells to various chemotherapeutic agents, underscoring its importance in cancer biology. Moreover, understanding the molecular mechanisms governing CDKN3's activity and interaction with other cell cycle regulators could provide novel insights into the development of targeted cancer therapies. Recent advances in recombinant protein technology have made it possible to produce CDKN3 in vitro, facilitating a more detailed investigation into its functional properties and potential as a therapeutic target. The exploration of CDKN3 in the context of cancer highlights its significance not only in cell proliferation control but also in the broader landscape of tumor biology and treatment strategies. As such, CDKN3 represents a compelling candidate for further research aimed at elucidating its role in oncogenesis and as a biomarker for cancer diagnosis and prognosis.
